Previous 10 | Next 10 |
In order to maintain adequate resources for its other development programs, MediciNova (MNOV) has decided to discontinue development of a SARS-CoV-2 vaccine for COVID-19.The company has conduced a review of its numerous development programs to determine the best allocation of resources going ...
LA JOLLA, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced an update on the development of a SARS-CoV-2 vaccine for...
Gain Therapeutics has filed to raise $40 million in a U.S. IPO. The firm is a preclinical biopharma developing treatments for lysosomal storage disorders. GANX has a number of research collaborations, but is still at a very early stage of development, so maybe more relevant for in...
LA JOLLA, Calif., Jan. 31, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the closing of the previously announced private placement...
MRK was developing two candidates in this category - with Themis they were working on a measles-based one, and the IAVI a VSV-based one. But the company announced today that they're dropping both of them after looking at the first human Phase I data. Adverse effects in the US, Israel,...
MediciNova (MNOV) surged 12.6% in after hours trade after 3D Investment Partners and 3D Opportunity Master Fund reported a 11.3% stake in the company.Both the parties believe that the company's common stock is undervalued and is an attractive investment.In the past one year, the sto...
The Japan Patent Office has granted a Notice of Allowance to MediciNova (MNOV) for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis ((ALS)). The patent is expected to expire no earlier than ...
LA JOLLA, Calif., Jan. 18, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan...
MediciNova (MNOV) has agreed to issue $20M in shares of its common stock to 3D Opportunity Master Fund, in a private placement transaction. Proceeds are expected to be used for the following three programs: To initiate a new clinical trial of MN-166 (ibudilast) for glioblastoma. To develop an...
LA JOLLA, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has entered into a Securities Purchase Agreement ...
News, Short Squeeze, Breakout and More Instantly...
Company to rededicate efforts toward updating stakeholders on corporate vision, strategy, and ongoing activities LA JOLLA, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market o...
LA JOLLA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S....
LA JOLLA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s collaborator, Gilbert Youssef, M.D....